BR112023025925A2 - Composições de liberação prolongada de mexiletina para administração oral - Google Patents
Composições de liberação prolongada de mexiletina para administração oralInfo
- Publication number
- BR112023025925A2 BR112023025925A2 BR112023025925A BR112023025925A BR112023025925A2 BR 112023025925 A2 BR112023025925 A2 BR 112023025925A2 BR 112023025925 A BR112023025925 A BR 112023025925A BR 112023025925 A BR112023025925 A BR 112023025925A BR 112023025925 A2 BR112023025925 A2 BR 112023025925A2
- Authority
- BR
- Brazil
- Prior art keywords
- mexiletine
- oral administration
- release
- prolonged
- release compositions
- Prior art date
Links
- 229960003404 mexiletine Drugs 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 2
- VLPIATFUUWWMKC-UHFFFAOYSA-N mexiletine Chemical compound CC(N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-UHFFFAOYSA-N 0.000 title 1
- VLPIATFUUWWMKC-SNVBAGLBSA-N (2r)-1-(2,6-dimethylphenoxy)propan-2-amine Chemical compound C[C@@H](N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-SNVBAGLBSA-N 0.000 abstract 3
- 238000013270 controlled release Methods 0.000 abstract 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 abstract 2
- 239000003456 ion exchange resin Substances 0.000 abstract 2
- 229920003303 ion-exchange polymer Polymers 0.000 abstract 2
- 239000000725 suspension Substances 0.000 abstract 2
- 206010061533 Myotonia Diseases 0.000 abstract 1
- 208000012905 Myotonic disease Diseases 0.000 abstract 1
- 238000013265 extended release Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202131026198 | 2021-06-11 | ||
| PCT/EP2022/065917 WO2022258842A1 (en) | 2021-06-11 | 2022-06-10 | Extended-release compositions of mexiletine for oral administration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023025925A2 true BR112023025925A2 (pt) | 2024-02-27 |
Family
ID=82258238
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023025925A BR112023025925A2 (pt) | 2021-06-11 | 2022-06-10 | Composições de liberação prolongada de mexiletina para administração oral |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240173272A1 (https=) |
| EP (1) | EP4351549A1 (https=) |
| JP (1) | JP2024521460A (https=) |
| CN (1) | CN117858702A (https=) |
| AU (1) | AU2022288145A1 (https=) |
| BR (1) | BR112023025925A2 (https=) |
| CA (1) | CA3221594A1 (https=) |
| CL (1) | CL2023003702A1 (https=) |
| CO (1) | CO2023017619A2 (https=) |
| MX (1) | MX2023014773A (https=) |
| WO (1) | WO2022258842A1 (https=) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD146547A5 (de) | 1978-07-15 | 1981-02-18 | Boehringer Sohn Ingelheim | Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen |
| CN101466390B (zh) * | 2006-06-15 | 2014-03-12 | 优时比制药有限公司 | 用于治疗难治性癫痫持续状态的肽类化合物 |
| CN101032462A (zh) | 2006-12-20 | 2007-09-12 | 浙江大学 | 盐酸美西律缓释制剂及制备方法 |
| WO2010149760A2 (en) | 2009-06-24 | 2010-12-29 | Shire Llc | Mexiletine amino acid and peptide prodrugs and uses thereof |
| US20120196933A1 (en) | 2010-12-23 | 2012-08-02 | Richard Franklin | Mexiletine prodrugs |
-
2022
- 2022-06-10 WO PCT/EP2022/065917 patent/WO2022258842A1/en not_active Ceased
- 2022-06-10 CA CA3221594A patent/CA3221594A1/en active Pending
- 2022-06-10 BR BR112023025925A patent/BR112023025925A2/pt unknown
- 2022-06-10 MX MX2023014773A patent/MX2023014773A/es unknown
- 2022-06-10 JP JP2023576212A patent/JP2024521460A/ja active Pending
- 2022-06-10 EP EP22734249.0A patent/EP4351549A1/en active Pending
- 2022-06-10 AU AU2022288145A patent/AU2022288145A1/en active Pending
- 2022-06-10 CN CN202280056092.8A patent/CN117858702A/zh active Pending
-
2023
- 2023-12-10 US US18/534,710 patent/US20240173272A1/en active Pending
- 2023-12-11 CL CL2023003702A patent/CL2023003702A1/es unknown
- 2023-12-15 CO CONC2023/0017619A patent/CO2023017619A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022288145A1 (en) | 2024-01-04 |
| MX2023014773A (es) | 2024-01-15 |
| CN117858702A (zh) | 2024-04-09 |
| CL2023003702A1 (es) | 2024-05-03 |
| EP4351549A1 (en) | 2024-04-17 |
| WO2022258842A1 (en) | 2022-12-15 |
| JP2024521460A (ja) | 2024-05-31 |
| CA3221594A1 (en) | 2022-12-15 |
| US20240173272A1 (en) | 2024-05-30 |
| CO2023017619A2 (es) | 2024-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20090887L (no) | Fremgangsmate for behandling og forebygging av mukositt | |
| BR112023002458A2 (pt) | Métodos de tratamento da gota | |
| Waters et al. | Long-term treatment with extended-release carbidopa–levodopa (IPX066) in early and advanced Parkinson’s disease: a 9-month open-label extension trial | |
| CN103298464A (zh) | 复方组合物 | |
| RU2018121615A (ru) | Модуляторы активности комплемента | |
| JP2020531550A5 (https=) | ||
| BR112021024886A2 (pt) | Métodos de tratar a doença de fabry em pacientes com insuficiência renal | |
| BR112022009283A2 (pt) | Métodos de tratamento do câncer do pulmão de células pequenas com formulações de lurbinectedina | |
| BRPI0518741A2 (pt) | uso de uma combinaÇço de uma droga diretamente metabolizada por ugt1a1 ou um seu sal farmaceuticamente aceitÁvel e atazanavir ou um seu sal farmaceuticamente aceitÁvel, e, combinaÇço farmacÊutica para administraÇço oral a um mamÍfero | |
| BR112023025925A2 (pt) | Composições de liberação prolongada de mexiletina para administração oral | |
| AU2015343060A1 (en) | Methods of treating Huntington's Disease using cysteamine compositions | |
| BR112019026029A2 (pt) | Formulações farmacêuticas orais de remogliflozina | |
| MX2022012693A (es) | Composicion que comprende metilfolato. | |
| JP2019535830A5 (https=) | ||
| Nasrallah | Are you neuroprotecting your patients? 10 Adjunctive therapies to consider | |
| MX2021008986A (es) | Metodos de tratamiento de un paciente con enfermedad de parkinson. | |
| RU2011113733A (ru) | Производные 1-амино-алкилциклогексана для лечения когнитивного нарушения при шуме в ушах | |
| PH12014000275A1 (en) | Antiviral pharmaceutical formulation for the effective treatment of dengue, influenza and hiv/aids | |
| BR112022018917A2 (pt) | Agente protetor da função renal | |
| Cristancho et al. | The role of quetiapine extended release in the treatment of bipolar depression | |
| WO2021205402A1 (en) | Endoxifen for the treatment of bipolar i disorder | |
| MX2021007324A (es) | Terapia oral con acido 6,8-bis-benciltio-octanoico. | |
| BR112022002949A2 (pt) | Composição farmacêutica para tratar insônia | |
| BR112022000571A2 (pt) | Composição farmacêutica e processo para preparação de uma composição farmacêutica compreendendo imatinibe ou seu sal farmaceuticamente aceitável e um ou mais excipientes farmaceuticamente aceitáveis em forma de pó | |
| WO2021205404A1 (en) | Endoxifen for the treatment of bipolar i disorder |